ALG-000184, Publications Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Asian and non Asian Subjects with Chronic Hepatitis B (CHB)
Other, Publications Hepatitis B Surface Antigen (HBsAg) is Significantly Reduced by the HBV small interfering RNA (siRNA) ALG-125755 in HBV Infected Cells and the AAV HBV Mouse Model
Publication, Publications Capsid Assembly Modulators as Antiviral Agents against HBV: Molecular Mechanisms and Clinical Perspectives
ALG-000184, Publications Safety, Pharmacokinetics (PK), and Antiviral Activity of the Capsid Assembly Modulator (CAM) ALG-000184 in Subjects with Chronic Hepatitis B (CHB)
Other, Publications Incorporation of Novel siRNA Chemistries Significantly Improves the Potency and Durability of HBV siRNAs in the AAV-HBV Mouse Model
ALG-055009, Publications Preclinical Pharmacokinetic Profiling of ALG-055009, a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of Nonalcoholic Steatohepatitis, and Prediction of its Human Pharmacokinetics
ALG-055009, Publications Development of a Novel Seven-Day Dosing Mouse Efficacy Model to Evaluate Thyroid Hormone Receptor Agonists for the Treatment of NASH
Preclinical, Publications ALG-005398 is a Potent Non-HAP Class I HBV Capsid Assembly Modulator that Strongly Reduces HBsAg Levels In Vivo
Publication, Publications Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection
Publication, Publications Label-Free Screening of SARS-CoV-2 NSP14 Exonuclease Activity Using SAMDI Mass Spectrometry